30 closest matches · ranked by relevance
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Progression Free Survival (PFS) — 255.921 days to progression
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Colorectal Neoplasms · Neoplasm Metastasis
Primary: Overall Survival (OS) — 12.06; 13.50 months — p=0.0032
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 1 participants
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
Colorectal Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5.59; 6.93 months
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I) — NA
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 5.3 percentage of participants
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Colorectal Neoplasms
Primary: Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment — 58.5; 18.7; 12.2; 2.4…
Colorectal Cancer · Metastatic Cancer
Primary: Number of Participants With Objective Tumor Response Through Week 16 — 5 Participants
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Colorectal Cancer
Primary: Objective Response Rate (ORR) During the Combination Therapy Phase — 29.2; 35.2; 46.3; 0 percentage of patients
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Colorectal Cancer
Primary: Progression Free Survival — 9.9; 10.3 Months
Colorectal Cancer
Primary: 12-Week Progression Free Survival — 18 Participants
Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 5.9; 3.9; 5.0; 4.9 months — p=0.0036
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Colorectal Cancer · Metastases
Primary: Objective Tumor Response Through Week 16 — 6 participants
Colorectal Cancer
Primary: Progression Free Survival — 5.8; 7.2; 7.8 Months
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Metastatic Colorectal Cancer
Primary: Rate of Patients Alive and Progression-free 6 Months After Inclusion. — 22 Nb of patients alive without progression
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 63; 42 percentage of participants with response